Press Release

18 May 2023

HitGen Announces Drug Discovery Research Agreement with ARase Therapeutics

CHENGDU, China, May 18, 2023 – Shanghai Stock Exchange listed company HitGen Inc. ("HitGen", SSE: 688222.SH) announced today that it has entered into a research agreement with ARase Therapeutics, Inc. ("ARase"), a biotechnology company developing first-in-class therapeutics targeting ADP-ribose hydrolases, novel targets that function in therapeutically proven cancer stress pathways. HitGen will utilize its DNA-encoded library (DEL) technology platform, centered around the design, synthesis and screening of DELs, to identify novel inhibitors of ARase’s validated oncology targets. HitGen will also support ARase programs from hit-to-lead chemistry to pre-clinical development.
28 April 2023

Infographic | HitGen FY2022 Annual Report

Infographic | HitGen FY2022 Annual Report
12 December 2022

HitGen Announces Research Agreement with Nitrase Therapeutics Focused on DNA-Encoded Library Based Drug Discovery

CHENGDU, China, December 12, 2022 – Shanghai Stock Exchange listed company HitGen Inc. (“HitGen”, SSE: 688222.SH) today announced that it has entered into a research agreement with Nitrase Therapeutics, Inc. (“Nitrase”), a biopharmaceutical company deploying its NITROME platform to build a pipeline of therapies targeting nitrases, which is a new class of enzymes discovered by Nitrase that are involved in a broad variety of diseases.
14 November 2022

Daewoong and HitGen Announce Research Collaboration Focused on DNA-Encoded Library Based Drug Discovery

CHENGDU, China, November 14, 2022 – Shanghai Stock Exchange listed company HitGen Inc. (“HitGen”, SSE:688222.SH) today announced that it has entered into a research collaboration agreement with DAEWOONG PHARMACEUTICAL Co., Ltd (“Daewoong”), a global healthcare group in the Republic of Korea, dedicated to improving the quality of patients' lives. HitGen will apply its DNA-encoded library (DEL) technology platform centered around the design, synthesis and screening of thousands of DELs that collectively comprise over 1.2 trillion small, drug-like molecules to discover compounds that bind to certain targets that Daewoong needs to discover for new drug development.
28 October 2022

Infographic | HitGen FY2022 Q3 Report

Infographic | HitGen FY2022 Q3 Report
20 October 2022

C4XD and HitGen to collaborate in inflammation hit identification project Initial project with option to expand collaboration on successful outputs

20 October 2022 – C4X Discovery Holdings plc (“C4XD”, AIM: C4XD), a pioneering Drug Discovery company, and Shanghai Stock Exchange listed company HitGen Inc. (“HitGen”, SSE: 688222.SH), a world leader in the development and application of DNA-encoded library (DEL) technology, today announce a research collaboration project to identify novel, small molecule hits against an inflammatory target for further C4XD development.
28 September 2022

Vernalis Research, a fully owned subsidiary of HitGen Inc., and Contera Pharma A/S announce a strategic collaboration in the field of RNA-targeting small molecules in neurology

Cambridge UK, and Copenhagen, Denmark, 27 September 2022 – Vernalis Research (“Vernalis”), a fully owned subsidiary of HitGen Inc., and Contera Pharma A/S (“Contera”) are pleased to announce a strategic drug discovery collaboration on an undisclosed target.
05 September 2022

Vernalis Research, a fully owned subsidiary of HitGen Inc., and Unison Medicines Inc. announce a research collaboration in the field of anti-infectives

Cambridge UK, and Boston, US, 5 September 2022 – Vernalis Research (“Vernalis”), a fully owned subsidiary of HitGen Inc., and Unison Medicines Inc. (“Unison”) are pleased to announce a research collaboration on an undisclosed bacterial target.
27 July 2022

LoQus23 and HitGen Announce Research Collaboration Focused on DNA-Encoded Library Based Drug Discovery

CHENGDU, China, July 27, 2022 – Shanghai Stock Exchange listed company HitGen Inc. (“HitGen”) today announced that it has entered into a research collaboration agreement with LoQus23 Therapeutics Ltd. (“LoQus23”), a private biotechnology company discovering small molecule therapies that target aberrant DNA damage repair to treat Huntington's disease and other triplet repeat diseases (TRDs). HitGen will apply its DNA-encoded library (DEL) technology platform to discover compounds that bind to certain targets that are of interest to LoQus23.
20 May 2022

Almac Discovery and HitGen Announce Strategic Research Collaboration

Almac Discovery, the research driven drug discovery company and a member of the Almac Group, today announced a new research collaboration with HitGen Inc. (SSE: 688222.SH), a world leader in the development and application of DNA-encoded library (DEL) technology for novel chemical equity (NCE) generation. The collaboration is focused on the identification of novel compounds against selected Deubiquitinating enzymes (DUB) targets of strategic interest to Almac.

News

Press Release

Questions?